Botanix continues work to finalize the clinical study report for...

Botanix continues work to finalize the clinical study report for its rosacea study with BTX 1702 and close out activities at the various clinical sites in Australia and New Zealand, as well as complete the data package for ethics approval for the BTX 1801 development program, following the announcement of positive data from the Phase 2a study. The Company's focus remains, however, on preparing for and securing the approval of SB given the near term commercial and revenue generating potential for that product.In parallel Botanix continues to explore opportunities to add soon to be approved and marketed products to its pipeline to bolster the revenue generation potential of the Company and to enhance its attractiveness, as both a stand-alone company or an M&A target.

What else can they say?